Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

NCT06864975 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Hemophilia a with Inhibitor

Interventions

DRUG: Advate®
DRUG: Advate®
DRUG: Advate®
DRUG: Advate®
DRUG: Advate®

Sponsor

Runhui WU